Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01017939 · ClinicalTrials.gov registry record · Phase 1
A Drug-Drug Interaction Study of Abiraterone Acetate Plus Prednisone With Dextromethorphan and Theophylline in Patients With Metastatic Castration-Resistant Prostate Cancer
A Phase 1 study, sponsored by Janssen Research & Development.
- Completed
- Registry status
- Phase 1
- Development phase
- 34
- Enrollment target
NCT01017939 is a Phase 1 study that has completed, run by Janssen Research & Development. The registered enrollment target is 34 participants.
The verdict
NCT01017939, a Phase 1 study, has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 34 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the effects of multiple doses of abiraterone acetate plus prednisone on the pharmacokinetics (study of what the body does to a drug) of single doses of dextromethorphan hydrobromide and theophylline in patients with castration resistant prostate cancer.
Interventions
- DRUG Theophylline
- DRUG Prednisone
- DRUG Abiraterone acetate
- DRUG Dextromethorphan hydrobromide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2010-01 |
| Est. Completion | 2012-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01017939
The ClinicalTrials.gov registry entry for NCT01017939 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Theophylline is the first listed.
NCT01017939 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01017939 about?
NCT01017939 is a clinical study titled "A Drug-Drug Interaction Study of Abiraterone Acetate Plus Prednisone With Dextromethorphan and Theophylline in Patients With Metastatic Castration-Resistant Prostate Cancer". The purpose of this study is to evaluate the effects of multiple doses of abiraterone acetate plus prednisone on the pharmacokinetics (study of what the body does to a drug) of single doses of dextromethorphan hydrobromide and theophylline in patients with castration resistant prostate cancer.
What is the current status of trial NCT01017939?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 34 participants. The study started on 2010-01. Estimated completion is 2012-04.
What interventions are being tested in trial NCT01017939?
The interventions under investigation include: Theophylline (DRUG), Prednisone (DRUG), Abiraterone acetate (DRUG), Dextromethorphan hydrobromide (DRUG).
Who is sponsoring clinical trial NCT01017939?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.